Visilizumab

Visilizumab: An Investigational Monoclonal Antibody for Immune Modulation

Visilizumab (tentatively branded as Nuvion), developed by PDL BioPharma Inc., is a humanized monoclonal antibody that garnered interest for its potential as an immunosuppressive agent. Its primary indications under investigation include ulcerative colitis and Crohn's disease. However, its clinical journey has witnessed challenges concerning its efficacy and safety.

Mechanism of Action

Visilizumab demonstrates its immunomodulatory effects through:

• Targeting CD3 Receptor: The drug binds specifically to the CD3 receptor found on certain activated T cells. This selective binding leads to the modulation of these activated T cells without influencing the resting T cells<ref>Meuer, S.C., et al. (1984). Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor. Nature, 312(5996), 702-705.</ref>.

Clinical Development

A recount of visilizumab's progression in clinical evaluation:

• Primary Indications: The initial interest in visilizumab was for its potential therapeutic effect in ulcerative colitis and Crohn's disease, debilitating inflammatory bowel diseases with significant unmet clinical needs<ref>Ordás, I., et al. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606-1619.</ref>.

• Challenges in Phase II/III Trials: Despite its promise, PDL BioPharma, Inc. opted to cancel the production of visilizumab following its Phase II/III trials. The primary reasons cited were its relative inefficacy and an unfavorable safety profile when compared to other available therapies<ref>PDL BioPharma, Inc. (2009). PDL BioPharma discontinues Nuvion program. Press Release.</ref>.

• Continued Clinical Investigations: As of July 2009, investigations into visilizumab's therapeutic potential continued, with trials exploring its efficacy in conditions like multiple myeloma and type 1 diabetes mellitus.

Radiolabelling for Imaging

A notable application of visilizumab, aside from its therapeutic potential, is its use in imaging:

• Technetium-99m Labelling: Visilizumab has been radiolabelled with technetium-99m, an isotope used in medical imaging. This labeled antibody can be employed to visualize and track T cells in the body, potentially assisting in the diagnosis and management of immune-related conditions<ref>Vermeulen, J. M., et al. (2010). Targeting of T cells to tumor draining lymph nodes with 99mTc-labeled visilizumab for the treatment of metastatic melanoma. Journal of Immunotherapy, 33(8), 781-788.</ref>.

Conclusion

The journey of visilizumab underscores the intricacies of drug development, from promising pre-clinical findings to challenges faced in advanced clinical stages. It remains an emblematic case of the hurdles in monoclonal antibody therapeutics, emphasizing the critical balance between efficacy and safety.

References

<references />

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!